To assess the possible usefulness of AMPK as a therapeutic target in GBS, we exploited the fact that the anti-diabetic drug metformin achieves its insulin-sensitizing effect primarily through AMPK activation [45]. Here, INS is linked to Guillain-Barre syndrome.